Filter By Category
Archives
Share on -
ASALHYDROMORPHONE
Generic Name: ASALHYDROMORPHONE
ABSTRACT -
Asalhydromorphone is an opioid-related name associated with hydromorphone-type chemistry. Publicly available approved clinical labeling and routine dosing information are limited. Because opioid-like agents can cause life-threatening respiratory depression and dependence, it should be treated as a restricted investigational or specialist-controlled substance unless an official local label is available.
DOSAGE -
- No approved routine dosage regimen could be confirmed.
- Do not use unless supplied under a lawful prescription, clinical protocol, or controlled-substance framework.
- Any dosing would require opioid-tolerability assessment, route-specific conversion, careful titration, and monitoring for sedation/respiratory depression.
- Never substitute for hydromorphone or other opioids by name similarity.
SIDE EFFECTS–
- Respiratory depression, sedation, dizziness, confusion, or coma
- Nausea, vomiting, constipation, dry mouth, itching, sweating, or urinary retention
- Hypotension, bradycardia, falls, or impaired driving ability
- Tolerance, physical dependence, withdrawal, misuse, addiction, or overdose
- Serotonin toxicity is possible with some opioid combinations by class
ALLERGIC REACTIONS -
- Allergy may present with rash, hives, facial swelling, wheezing, or anaphylaxis.
- Opioids can also cause non-allergic histamine-related itching or flushing; severe symptoms still need urgent evaluation.
DRUG INTERACTIONS-
- Alcohol, benzodiazepines, sedatives, gabapentinoids, muscle relaxants, antipsychotics, and other opioids markedly increase respiratory-depression risk.
- MAO inhibitors, serotonergic antidepressants, CYP inhibitors/inducers, and anticholinergics require review.
- Naltrexone, buprenorphine, or mixed agonist-antagonists can precipitate withdrawal or reduce analgesia.
PREAUTIONS–
- Assess opioid tolerance, respiratory disease, sleep apnea, hepatic/renal impairment, head injury, ileus, pregnancy, substance-use history, and concomitant CNS depressants.
- Monitor respiratory rate, sedation score, oxygenation, blood pressure, bowel function, and misuse risk.
- Provide naloxone access if clinically appropriate.
- Use secure storage and controlled dispensing.
WARNINGS –
- Opioid-like agents can cause fatal respiratory depression, especially during initiation, dose escalation, or combination with CNS depressants.
- Risk of addiction, abuse, misuse, neonatal opioid withdrawal, and overdose must be assumed unless proven otherwise.
- Seek emergency care for slow breathing, extreme sleepiness, blue lips, or unresponsiveness.
- Keep locked away and out of reach of children.
Share on -
. Developed by